Global Gastrointestinal Bleeding Therapeutic Devices Market Size By Type (Endoscopic Hemostatic Devices, Closure Devices), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 t...

The Global Gastrointestinal (GI) Bleeding Therapeutic Devices Market was valued at USD 850 million in 2023 and is projected to reach USD 1.52 billion by 2031, growing at a CAGR of 7.4% during the forecast period from 2023 to 2031. The rising prevalence of gastrointestinal disorders, growing elderly population, and the increasing adoption of minimally invasive procedures are the primary factors driving the market growth. Gastrointestinal bleeding is a medical emergency requiring timely diagnosis and intervention. Therapeutic devices, including hemostatic clips, thermal coagulation devices, and argon plasma coagulators, play a crucial role in managing and stopping active GI bleeding, enhancing patient outcomes and reducing hospitalization durations.

Drivers:

1. Increasing Incidence of GI Disorders:

The growing burden of peptic ulcers, esophageal varices, diverticulosis, and colorectal cancer is contributing to a rise in cases of gastrointestinal bleeding. This trend is significantly driving demand for effective therapeutic devices.

2. Rise in Geriatric Population:

Aging populations are more prone to gastrointestinal ailments, necessitating frequent use of endoscopic procedures and therapeutic tools to manage bleeding episodes.

3. Advancements in Endoscopic Technologies:

Modern devices enable real-time bleeding localization and rapid hemostasis, improving procedural success rates and expanding treatment capabilities in both acute and chronic GI bleeding scenarios.

Restraints:

1. High Device and Procedural Costs:

The high cost of endoscopic therapeutic devices and related procedures can limit accessibility in low- and middle-income countries, restricting broader market penetration.

2. Limited Trained Professionals:

Successful use of therapeutic GI bleeding devices requires specialized skills, and a shortage of trained endoscopy professionals remains a barrier, especially in rural and underserved areas.

Opportunity:

1. Emerging Markets and Healthcare Infrastructure Expansion:

Asia-Pacific and Latin America present significant growth opportunities due to ongoing healthcare investments, increasing medical tourism, and rising awareness of gastrointestinal health.

2. Shift Toward Non-Invasive and Outpatient Procedures:

The growing preference for minimally invasive endoscopic techniques and outpatient care is fostering adoption of GI bleeding therapeutic devices that offer quick recovery and reduced patient burden.

Market by System Type Insights:

The Mechanical Devices segment, which includes hemostatic clips and band ligation devices, dominated the market in 2023 due to their high efficacy in achieving immediate bleeding control. However, the Thermal Coagulation Devices segment is expected to witness the fastest growth owing to technological improvements and increased usage in upper GI bleeding treatments.

Market by End-Use Insights:

The Hospitals segment held the largest revenue share in 2023, accounting for over 55% of the market. Hospitals are often the first point of treatment for emergency GI bleeding cases, equipped with advanced endoscopy suites. The Ambulatory Surgical Centers (ASCs) segment is poised for notable growth, driven by the rise in same-day minimally invasive procedures and favorable reimbursement frameworks.

Market by Regional Insights:

North America led the market in 2023, thanks to the presence of major device manufacturers, high healthcare spending, and growing cases of GI disorders. Asia-Pacific is projected to exhibit the highest CAGR during the forecast period due to increasing awareness, expansion of endoscopic services, and supportive government initiatives for healthcare infrastructure development.

Competitive Scenario:

Key players in the global gastrointestinal bleeding therapeutic devices market include Boston Scientific Corporation, Olympus Corporation, Cook Medical, CONMED Corporation, Medtronic plc, Erbe Elektromedizin GmbH, and Pentax Medical. These companies focus on technological innovation, global expansion, and strategic acquisitions. For instance:

In 2023, Boston Scientific introduced a next-generation hemostatic spray device for non-contact bleeding management.

In 2024, Olympus launched a compact bipolar hemostasis probe tailored for outpatient clinics.

In 2025, Medtronic expanded its endoscopic product line through a partnership with a leading Asian medtech company, increasing its regional market presence.

Scope of Work – Global Gastrointestinal Bleeding Therapeutic Devices Market

Report Metric Details

Market Size (2023) USD 850 million

Projected Market Size (2031) USD 1.52 billion

CAGR (2023–2031) 7.4%

Market Segments By System Type (Mechanical, Thermal, Topical), End-use (Hospitals, ASCs, Specialty Clinics), Region

Growth Drivers Increasing GI disorder prevalence, aging population, minimally invasive procedures

Opportunities Emerging markets, shift to outpatient and non-invasive care

Key Market Developments:

2023: Boston Scientific launched EndoClot Ultra, a novel hemostatic powder for immediate bleeding control in acute GI emergencies.

2024: Olympus unveiled an AI-integrated endoscopy system with real-time bleeding localization features.

2025: Cook Medical signed a distribution agreement to expand its presence in Latin American markets for its therapeutic GI portfolio.

FAQs:

1. What is the current market size of the Global Gastrointestinal Bleeding Therapeutic Devices Market?

The market was valued at USD 850 million in 2023.

2. What is the major growth driver of the Global Gastrointestinal Bleeding Therapeutic Devices Market?

The increasing prevalence of gastrointestinal disorders and advancements in minimally invasive technologies are major growth drivers.

3. Which is the largest region during the forecast period in the Global Gastrointestinal Bleeding Therapeutic Devices Market?

North America is expected to remain the largest region due to advanced healthcare infrastructure and high procedure volumes.

4. Which segment accounted for the largest market share in the Global Gastrointestinal Bleeding Therapeutic Devices